XML 19 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2016
Mar. 31, 2016
Jan. 31, 2016
May 31, 2015
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2013
Dec. 31, 2010
Feb. 20, 2020
Dec. 31, 2019
Related-Party Transactions (Textual) [Abstract]                    
Long-term other assets         $ 2,480,087         $ 2,672,024
GeneOne Life Sciences                    
Related-Party Transactions (Textual) [Abstract]                    
Investment owned (in shares)         1,644,155          
Payment received for license granted               $ 3,000,000    
Term             20 years      
Milestone-based ownership target     35.00% 35.00%            
Revenue from related parties         $ 31,000 $ 31,000        
Operating expenses related to affiliated entity         606,000 1,100,000        
Accounts receivable         3,000         128,000
Accounts payable and accrued liability         2,000         511,000
Long-term other assets         294,000         284,000
Director                    
Related-Party Transactions (Textual) [Abstract]                    
Term   5 years                
Revenue from related parties           838,000        
Operating expenses related to affiliated entity         362,000 487,000        
Accounts receivable         626,000         616,000
Expenses to reimburse   $ 3,100,000                
Awarded amount $ 6,100,000                  
Contra-research and development expense         619,000          
Accounts payable/accrued liabilities         262,000         219,000
Deferred grant funding, from affiliate         794,000          
Plumbline Life Sciences                    
Related-Party Transactions (Textual) [Abstract]                    
Revenue from related parties           $ 24,000        
Accounts receivable         $ 5,000         $ 589,000
Ownership percentage                 19.90%  
Plumbline Life Sciences | Available-for-sale Securities                    
Related-Party Transactions (Textual) [Abstract]                    
Investment owned (in shares)         597,808          
Investment owned, additional shares acquired (in shares)                 202,050